logo
  

PTC Receives Positive CHMP Opinion For Upstaza For Treatment Of AADC Deficiency

PTC Therapeutics Inc. (PTCT) said that Upstaza received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA.

Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain, the company said in a statement.

PTC expects the European Commission to ratify the marketing authorization for Upstaza under exceptional circumstances in about two months. The decision will be applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. air travel industry is going through its worst crisis since the troubled travel time during the peek pandemic struggles, with thousands of flights across the country being cancelled or getting delayed. The aviation crisis, as millions are preparing to travel during the upcoming July 4th holiday weekend, is mainly attributed to the staffing issues at airlines, ... The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert for Siluriformes products imported by Carlstadt, New Jersey- based Grand BK Corp. The products were imported from Korea, a country ineligible to export Siluriformes products to the United States. Blount Fine Foods is recalling a limited amount of Panera at Home Southwest Corn Chowder citing undeclared wheat allergen, the U.S. Food and Drug Administration said. The recall involves a single lot of 16 oz. product with UPC Code 077958690812, lot number 042122-2K and "Use By" date of 6/30/22 that comes around 2,569 cases in total. The recall is limited to 1 SKU of 16 oz.
Follow RTT